GSK and Barclays Launch Partnership for Zambia

mia.burns GSK and Barclays form partnership to increase access to healthcare and promote economic development in Zambia Issued: Friday 27 September 2013, London, UK & New ...

Rise of personalized drugs means fewer ‘dinosaur’ trials

Damian Garde Now that targeted therapies like Roche's Zelboraf and Bayer's Stivarga have raced through the FDA and into patients' hands, drug developers are relying less ...

Merck gives up on unsuccessful Januvia combo drug Juvisync

Tracy Staton As it announced cuts to its full-year sales forecast in July, Merck was able to point to growth in sales of Januvia and its offshoots, if only in the low-single-digit range. FiercePharma ...

Merck KGaA Shares More Management Changes

mia.burns Merck KGaA Announces Further Management Changes to Drive Pharmaceutical Business Growth •Stefan Oschmann to focus on role as Head of Pharmaceuticals in charge of the biopharmaceutical ...

Great expectations build for PCSK9 blockbuster prospect from Sanofi, Regeneron

John Carroll In an industry like pharma, you're only as good as your next big Phase III study. And hopes are running very, very high for the first round of late-stage results on ...

Japan authorities digging deeper into Novartis’ use of flawed Diovan study

Eric Palmer Swiss drugmaker Novartis has repeatedly apologized after learning that a company employee was affiliated with a study in Japan of blockbuster Diovan as a statistician without ...

U.K.’s nod to J&J’s Caelyx comes even as shortages expected

Eric Palmer The U.K. drug price watchdog today gave Johnson & Johnson's Caelyx the distinction of being one of only two drugs it believes should be funded by the National Health ...

Sanofi and Aviesan Renew French Agreement

mia.burns Sanofi and Aviesan Renew their Agreement to Accelerate Research in France -Three-year renewal of the cooperation protocol- Paris, France-September 27, 2013- Sanofi (EURONEXT: ...

Third Rock’s path to success lined with patience, rigor and T-shirts

Damian Garde Looking at this year's boom in high-dollar biotech IPOs, you can't miss the fingerprints of Third Rock Ventures, with three of the hottest market debuts coming ...

Takeda Loses Second Actos Trial Over Bladder Cancer Risks

esilverman A Maryland state court jury ordered Takeda Pharmaceuticals to pay $ 1.7 million in damages for failing to properly warn a former US Army translator and his physician ...

Inotek snags $21M for PhII glaucoma drops

Damian Garde Lexington, MA's Inotek has pulled down a $ 21 million round to advance its lead product, designed to ease in-eye pressure for glaucoma patients. FierceBiotech News

Boehringer’s China expansion hits as probes leave market in turmoil

Eric Palmer Germany's Boehringer Ingelheim two years ago started on a major addition to its operations in China as that rapidly expanding market looked like the promised land to ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS